نتایج جستجو برای: blocker treatment

تعداد نتایج: 1407046  

Journal: :European urology 2013
Claudius Füllhase Christopher Chapple Jean-Nicolas Cornu Cosimo De Nunzio Christian Gratzke Steven A Kaplan Michael Marberger Francesco Montorsi Giacomo Novara Matthias Oelke Hartmut Porst Claus Roehrborn Christian Stief Kevin T McVary

BACKGROUND Several drugs are approved for the treatment of lower urinary tract symptoms (LUTS) in men, but these are mostly used by clinicians as monotherapies. The combination of different compounds, each of which targets a different aspect of LUTS, seems appealing. However, only few clinical trials have evaluated the effects of combination therapies. OBJECTIVE This systematic review analyze...

Journal: :Cardiology in review 2003
Wilbert S Aronow

American College of Cardiology/American Heart Association class I recommendations for treating patients with heart failure (HF) and abnormal left ventricular ejection fraction are diuretics in patients with fluid retention, an angiotensin-converting enzyme (ACE) inhibitor unless contraindicated, a beta-blocker unless contraindicated, digoxin for the treatment of symptoms of HF, and withdrawal o...

Asieh Firoozeh-Moghadam Atefeh Shirinbak Farzin Hadizadeh, Mahmoud Seifi Mohammad Bagher Gharedaghi Mohsen Imenshahidi,

ATP-sensitive potassium (KATP) channel openers have a relaxation effect due to the lower cellular membrane potential and inhibit calcium influx. There has been considerable interest in exploring KATP channel openers in the treatment of various diseases such as cardiovascular, cerebrovascular, and urinary system disease and premature labor. The purpose of this study was to synthesize 3,3,6,6-tet...

Farzanehsadat Minoo, Mohammad Hossein Shojamoradi, Mohammad Taghi Najafi,

Background: Resistant hypertension is defined when the blood pressure remains elevated above the therapeutic target levels despite the use of three antihypertensive agents including calcium channel blocker (CCB), renin-angiotensin system (RAS) blocker and a diuretic. These drugs should be used at maximally tolerated doses and white coat effect and non-adherence should also be excluded. In this ...

Journal: :International heart journal 2006
Takuya Okada Makoto Nagai Ikuo Taniguchi Mamoru Kuno Satoshi Imamoto Shingo Seki Masayuki Taniguchi Seibu Mochizuki

Treatment with an angiotensin blocker (ARB) and an aldosterone blocker has been shown to have beneficial effects on cardiac remodeling in several cardiac diseases. It is still not clear whether the combination of these drugs is more effective against cardiac remodeling than the use of either agent alone. We examined the effects of combined treatment with valsartan, an ARB, and spironolactone, a...

Journal: :Heart 1999
K S Spargias A S Hall D C Greenwood S G Ball

OBJECTIVES To examine clinical outcomes associated with optional beta blockade in a population of patients with evidence of heart failure after myocardial infarction. DESIGN AND PATIENTS Data from the acute infarction ramipril efficacy (AIRE) study were analysed retrospectively. At baseline 22.3% of the patients were receiving a beta blocker. To minimise confounding, beta blocker and diuretic...

Journal: :Circulation. Cardiovascular genetics 2009
Amber L Beitelshees Hrishikesh Navare Danxin Wang Yan Gong Jennifer Wessel James I Moss Taimour Y Langaee Rhonda M Cooper-DeHoff Wolfgang Sadee Carl J Pepine Nicolas J Schork Julie A Johnson

BACKGROUND The gene encoding the target of calcium channel blockers, the alpha1c-subunit of the L-type calcium channel (CACNA1C), has not been well characterized, and only small pharmacogenetic studies testing this gene have been published to date. METHODS AND RESULTS Resequencing of CACNA1C was performed followed by a nested case-control study of the INternational VErapamil SR/trandolapril S...

Journal: :Hypertension 2013
Caitrin W McDonough Yan Gong Sandosh Padmanabhan Ben Burkley Taimour Y Langaee Olle Melander Carl J Pepine Anna F Dominiczak Rhonda M Cooper-Dehoff Julie A Johnson

We sought to identify novel pharmacogenetic markers associated with cardiovascular outcomes in patients with hypertension on antihypertensive therapy. We genotyped a 1:4 case:control cohort (n=1345) on the Illumina HumanCVD Beadchip from the INternational VErapamil SR-Trandolapril STudy (INVEST), where participants were randomized to a β-blocker strategy or a calcium channel blocker strategy. G...

Journal: :Hypertension 1994
S W Rabkin M W Huff C Newman D Sim S G Carruthers

A randomized double-blind trial comparing the alpha-adrenergic blocker doxazosin and the beta-adrenergic blocker atenolol was completed by 131 patients with mild to moderate hypertension. Blood pressure and fasting blood lipids were determined at baseline and 4, 12, and 24 weeks of treatment. At entry, plasma lipids and lipoproteins were similar in those patients randomized to doxazosin or aten...

Journal: :Journal of Pharmacognosy and Phytochemistry 2023

1,4 Dihydropyridines are very versatile compounds and have important role as therapeutic agents. The 1, 4 (1,4 DHPs) well known calcium channel blocker their use in treatment of cardiovascular diseases is common. These also to antimicrobial activities. N-heterocyclic represent framework for agricultural pharmaceutical industries. antibacterial antifungal Hence, the substituted 4- Dihydropyridin...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید